Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
- IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients more "Good On" time with fewer doses
Amneal Pharmaceuticals, Inc. (NYSE:AMRX)
Amneal Pharmaceuticals Granted FDA Orange Book Approval For VASOPRESSIN
https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=212944#181
Recap: Amneal Pharmaceuticals Q2 Earnings
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q2 earnings results on Friday, August 5, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell
• Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Amneal Pharma Reports Achieved Its Third US Biosimilar Approval With FYLNETRA
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Biologics License